Total Payments
$2.7M
2024 Payments
$396,925
Companies
33
Transactions
4,738
Payment Breakdown by Category
Other$2.1M (76.4%)
Travel$451,057 (16.6%)
Consulting$116,960 (4.3%)
Food & Beverage$73,670 (2.7%)
Education$122.25 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.1M | 905 | 76.3% |
| Travel and Lodging | $451,057 | 1,751 | 16.6% |
| Consulting Fee | $116,960 | 36 | 4.3% |
| Food and Beverage | $73,670 | 2,040 | 2.7% |
| Honoraria | $4,400 | 2 | 0.2% |
| Education | $122.25 | 4 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | $807,421 | 829 | $0 (2024) |
| Allergan, Inc. | $502,291 | 1,025 | $0 (2021) |
| ABBVIE INC. | $426,435 | 746 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $337,617 | 741 | $0 (2024) |
| ITI, Inc. | $275,411 | 357 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $111,466 | 246 | $0 (2024) |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $105,908 | 160 | $0 (2024) |
| Takeda Pharmaceuticals America, Inc. | $54,099 | 85 | $0 (2017) |
| Axsome Therapeutics, Inc. | $39,743 | 60 | $0 (2024) |
| Vanda Pharmaceuticals Inc. | $31,621 | 67 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $396,925 | 637 | Teva Pharmaceuticals USA, Inc. ($127,649) |
| 2023 | $450,787 | 713 | AbbVie Inc. ($172,297) |
| 2022 | $322,764 | 563 | ABBVIE INC. ($112,977) |
| 2021 | $258,509 | 420 | AbbVie Inc. ($91,879) |
| 2020 | $211,301 | 329 | Teva Pharmaceuticals USA, Inc. ($100,933) |
| 2019 | $411,940 | 715 | Teva Pharmaceuticals USA, Inc. ($189,008) |
| 2018 | $402,920 | 771 | Allergan Inc. ($132,992) |
| 2017 | $265,809 | 590 | Allergan Inc. ($145,567) |
All Payment Transactions
4,738 individual payment records from CMS Open Payments — Page 1 of 190
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $90.80 | General |
| 12/19/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $21.79 | General |
| 12/11/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $16.13 | General |
| Category: CNS | ||||||
| 12/11/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $4.86 | General |
| Category: CNS | ||||||
| 12/10/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,680.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/10/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $30.32 | General |
| Category: PSYCHIATRY | ||||||
| 12/10/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | In-kind items and services | $27.63 | General |
| Category: SCHIZOPHRENIA | ||||||
| 12/09/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $19.21 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/05/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,940.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/05/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/05/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | In-kind items and services | $1,019.63 | General |
| Category: PSYCHIATRY | ||||||
| 12/05/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | In-kind items and services | $435.25 | General |
| Category: PSYCHIATRY | ||||||
| 12/05/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | In-kind items and services | $226.46 | General |
| Category: PSYCHIATRY | ||||||
| 12/05/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | In-kind items and services | $226.44 | General |
| Category: PSYCHIATRY | ||||||
| 12/05/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | Cash or cash equivalent | $124.34 | General |
| Category: PSYCHIATRY | ||||||
| 12/05/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $71.67 | General |
| Category: PSYCHIATRY | ||||||
| 12/05/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $12.32 | General |
| Category: PSYCHIATRY | ||||||
| 12/04/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,620.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/04/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,308.50 | General |
| Category: PSYCHIATRY | ||||||
| 12/04/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/04/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | In-kind items and services | $226.43 | General |
| Category: PSYCHIATRY | ||||||
| 12/04/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | In-kind items and services | $226.43 | General |
| Category: PSYCHIATRY | ||||||
| 12/04/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | In-kind items and services | $141.98 | General |
| Category: PSYCHIATRY | ||||||
| 12/04/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | In-kind items and services | $141.98 | General |
| Category: PSYCHIATRY | ||||||
| 12/04/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: PSYCHIATRY | ||||||
About Dr. Arvinder Pal Walia, M.D
Dr. Arvinder Pal Walia, M.D is a Psychiatry healthcare provider based in Austin, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1427163617.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Arvinder Pal Walia, M.D has received a total of $2.7M in payments from pharmaceutical and medical device companies, with $396,925 received in 2024. These payments were reported across 4,738 transactions from 33 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($2.1M).
Ad
Practice Information
- Specialty Psychiatry
- Location Austin, TX
- Active Since 08/20/2006
- Last Updated 06/08/2023
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1427163617
Products in Payments
- VRAYLAR (Drug) $928,713
- AUSTEDO (Drug) $620,321
- CAPLYTA (Drug) $381,319
- REXULTI (Drug) $342,641
- Austedo XR (Drug) $160,413
- Trintellix (Drug) $155,511
- Auvelity (Drug) $39,743
- FANAPT (Drug) $31,316
- UZEDY (Drug) $25,024
- LATUDA (Drug) $7,345
- Vyvanse (Drug) $5,590
- Dayvigo (Drug) $4,588
- VYVANSE (Drug) $4,007
- SUNOSI (Drug) $1,350
- ARISTADA (Drug) $841.14
- TRINTELLIX (Drug) $717.54
- SD809-TD (Drug) $591.83
- Azstarys (Drug) $503.09
- SPRAVATO (Drug) $354.86
- INGREZZA (Drug) $244.29
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Austin
Dr. Donald Garcia, Md, MD
Psychiatry — Payments: $4.0M
Psychiatry $4.0M
Charles Nemeroff, Md Phd, MD PHD
Psychiatry — Payments: $400,808
Psychiatry $400,808
Dr. Divyansu Patel, M.d, M.D
Psychiatry — Payments: $319,461
Psychiatry $319,461
Frank Floca, Md, MD
Psychiatry — Payments: $99,177
Psychiatry $99,177
Dr. Charles Sweet, M.d., M.p.h, M.D., M.P.H
Psychiatry — Payments: $88,371
Psychiatry $88,371
Dr. David Brown, M.d, M.D
Psychiatry — Payments: $45,241
Psychiatry $45,241